Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Enzymes, Transferase » Anti -Factor XIIIa (Coagulation Factor XIII A Chain, Coagulation Factor XIIIa, Coagulation Factor XIII A1 Polypeptide, F13A, F13A1, bA525O21.1, Fibrinoligase, Protein-glutamine gamma-glutamyltransferase A Chain, Transglutaminase A Chain, TGase)

Anti -Factor XIIIa (Coagulation Factor XIII A Chain, Coagulation Factor XIIIa, Coagulation
Factor XIII A1 Polypeptide, F13A, F13A1, bA525O21.1, Fibrinoligase, Protein-glutamine
gamma-glutamyltransferase A Chain, Transglutaminase A Chain, TGase)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Polyclonal Rabbit Serum E
Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.
Catalog #F0019-50M
Antibody Titer Precipitin titer not less than 1:32 when tested against appropriate concentrations of the antigen in agar-block immunodiffusion titration. The titre is further assayed by quantitative precipitin analysis incubating serial dilutions of the antiserum with normal plasma and measuring the residual antigen. The amount of Factor XIII precipitated by 1ml antiserum is about 10U.
ApplicationsSuitable for use in ELISA, Immunoelectrophoresis, Immunoelectrodiffusion and Radial Immunodiffusion (single and double). Other applications not tested.
Recommended DilutionImmunoelectrophoresis (agarose plates): 120ul antiserum per 2ul plasma or equivalent
Double Radial Immunodiffusion: Use a rosette arrangement with 10ul antiserum in 3mm
diameter center well and 2ul plasma samples (neat and serially diluted) in 2mm diameter
peripheral wells.
Electroimmunodiffusion: 1-2% antiserum depending on the test arrangement.
Optimal dilutions to be determined by the researcher.
Storage and StabilityLyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clone TypePolyclonal
IsotypeIgG
HostRabbit
SourceHuman
ConcentrationNot determined
FormSupplied as a lyophilized powder (delipidated, heat-inactivated stable whole serum). Preservative free. Reconstitute with 1ml sterile ddH2O. Further dilutions can be made with PBS, pH 7.2.
PuritySerum. Whole serum has been immunoaffinity adsorbed using insolubilized antigens to eliminate unwanted cross-reactivities.
ImmunogenHighly purified human Factor XIII-A
SpecificityRecognizes human Coagulation Factor XIII-A. The defined antibody reactivity is restricted to Factor XIII and FXIIIa in plasma and to platelet FXIII. Assay by immunoprecipitation techniques showed a reaction of full identity with A subunits of Factor XIII. No reaction was obtained with Factor XIII-depleted plasma and with B subunits.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links